ORKA - Oruka Therapeutics, Inc.
44.48
-0.980 -2.203%
Share volume: 885,714
Last Updated: 03-27-2026
Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances:
-0.05%
PREVIOUS CLOSE
CHG
CHG%
$45.46
-0.98
-0.02%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 04-25-2024 | 08-01-2024 | 11-13-2024 | 05-14-2025 | 08-11-2025 | 11-12-2025 | 03-12-2026 | |
| Total revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| nan% | nan% | nan% | nan% | nan% | nan% | |||
| Operating expenses | 2.482 M | 3.122 M | 29.449 M | 25.086 M | 28.429 M | 34.105 M | 34.431 M | |
| Selling general and admin | 2.317 M | 2.992 M | 3.758 M | 5.161 M | 4.342 M | 5.117 M | 6.791 M | |
| Research and development | 165.000 K | 130.000 K | 25.691 M | 19.925 M | 24.087 M | 28.988 M | 27.640 M | |
| Total expenses | 2.482 M | 3.122 M | 29.449 M | 25.086 M | 28.429 M | 34.105 M | 34.431 M | |
| 25.79% | 843.27% | -14.82% | 13.33% | 19.97% | 0.96% | |||
| Operating income | -2.482 M | -3.122 M | -29.449 M | -25.086 M | -28.429 M | -34.105 M | -34.431 M | |
| Ebit | -2.482 M | -3.122 M | 0.000 | 0.000 | 0.000 | 0.000 | -34.432 M | |
| Pretax income | -2.009 M | -2.678 M | -27.293 M | -20.999 M | -24.574 M | -30.277 M | -29.583 M | |
| 33.30% | 919.16% | -23.06% | 17.02% | 23.21% | -2.29% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -2.009 M | -2.678 M | -27.293 M | -20.999 M | -24.574 M | -30.277 M | -29.583 M | |
| -33.30% | -919.16% | 23.06% | -17.02% | -23.21% | 2.29% |